TT10

Unassigned

New Medicines

Advanced nasopharyngeal cancer - first-line in combination with gemcitabine + carboplatin

Information

New molecular entity
Tessa Therapeutics
Tessa Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Ex vivo activated and expanded, autologous Epstein-Barr virus (EBV) antigen-specific cytotoxic T-lymphocytes
Pharyngeal cancer is relatively uncommon in England and Wales but higher among those with a South Asian background. Nasopharyngeal carcinoma is endemic in Asia and is aetiologically associated with Epstein-Barr virus (EBV). During the past decades, the overall five-year survival rate has improved from 60% to 80% [1].
Advanced nasopharyngeal cancer - first-line in combination with gemcitabine + carboplatin
Intravenous infusion